Recruiting

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

ClinicalTrials.gov IDNCT05652569

PhaseNot Applicable

Enrollment5000

SponsorGerman Cancer Research Center

Age14 Years

SexALL

I'm interested View official listing

Conditions studied

Metastatic Breast Cancer

About this study

CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions. Eligible are all metastatic breast cancer patients (independent of gender), irrespective of molecular subtype. At initial diagnosis of distant metastasis or progress at disease progression, biopsy samples from a prognostic-relevant metastasis are retrieved during standard-of-care procedures for central analyses, together with blood samples. In parallel to all standard-diagnostic measures, genomic and transcriptomic profiling is conducted to infer the underlying biology of the disease and identify patients who might profit from biomarker-guided interventions in clinical trials. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform to i) identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) couple the observational, diagnostic registry platform to an increasing number of independent, biomarker-stratified clinical therapy trials (CATCH-GUIDE).

Interventions

Other: Genomic Profiling / Sequencing — Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions

Primary outcomes

Setup of the molecular profiling diagnostic platform and feasibility of genomic profiling in metastatic breast cancer. (31/12/2030)
Total number of patients eligible for clinical trials and targeted therapies based on clinical characteristics and comprehensive tumor features. (31/12/2030)

Eligibility information

Inclusion Criteria: * Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF) * Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines) * Patients, who agreed to and were able to sign the informed consent form. Exclusion Criteria: * Early breast cancer * Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient * Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Study locations

University Hospital Augsburg, Augsburg, Germany
Charité, Berlin, Germany
University Hospital Köln, Cologne, Germany
Medical Faculty and University Hospital Carl Gustav Carus, Dresden, Germany
University Hospital Erlangen, Erlangen, Germany
University Hospital Essen, Essen, Germany
National Center for Tumor Diseases, Heidelberg, Germany
Caritas Hospital St. Josef, Regensburg, Germany
Robert-Bosch-Krankenhaus Stuttgart, Stuttgart, Germany
University Hospital Tübingen, Tübingen, Germany

Showing 10 of 12 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.